{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:19:53Z","timestamp":1788391193963,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hoc.2026.05.020","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:27:36Z","timestamp":1788388056000},"page":"751-764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immuno-Oncology"],"prefix":"10.1016","volume":"40","author":[{"given":"Shiruyeh","family":"Schokrpur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L.","family":"Roland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip Pravin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.hoc.2026.05.020_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/bjs\/znac050","article-title":"Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient\/microsatellite instability-high locally advanced, non-metastatic colorectal cancer","volume":"109","author":"Kothari","year":"2022","journal-title":"Br J Surg"},{"issue":"25","key":"10.1016\/j.hoc.2026.05.020_bib2","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 Blockade in Mismatch Repair\u2013Deficient, Locally Advanced Rectal Cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"issue":"7934","key":"10.1016\/j.hoc.2026.05.020_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.hoc.2026.05.020_bib4","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMc2203316","article-title":"Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Ganguly","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.020_bib5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2026.05.020_bib6","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1186\/s12885-018-4829-0","article-title":"Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma","volume":"18","author":"Keung","year":"2018","journal-title":"BMC Cancer"},{"issue":"7867","key":"10.1016\/j.hoc.2026.05.020_bib7","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.020_bib8","doi-asserted-by":"crossref","first-page":"e001014","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.020_bib9","first-page":"4058","article-title":"CD3\/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3\/TCR signaling","volume":"161","author":"Hannier","year":"1998","journal-title":"J Immunol Baltim Md 1950"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.020_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12032-014-0082-9","article-title":"The effect of immune microenvironment on the progression and prognosis of colorectal cancer","volume":"31","author":"Chen","year":"2014","journal-title":"Med Oncol Northwood Lond Engl"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.020_bib11","doi-asserted-by":"crossref","first-page":"e1239005","DOI":"10.1080\/2162402X.2016.1239005","article-title":"LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma","volume":"5","author":"Deng","year":"2016","journal-title":"OncoImmunology"},{"issue":"13","key":"10.1016\/j.hoc.2026.05.020_bib12","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1158\/1078-0432.CCR-14-2926","article-title":"Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer","volume":"21","author":"Giraldo","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2026.05.020_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jim.2018.02.003","article-title":"Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction","volume":"456","author":"Bhagwat","year":"2018","journal-title":"J Immunol Methods"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.020_bib14","first-page":"4899","article-title":"Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma","volume":"190","author":"Goding","year":"2013","journal-title":"J Immunol Baltim Md 1950"},{"issue":"29","key":"10.1016\/j.hoc.2026.05.020_bib15","doi-asserted-by":"crossref","first-page":"27359","DOI":"10.18632\/oncotarget.4751","article-title":"LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8 + T cell signaling and dampen antitumor immunity in a murine ovarian cancer model","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.020_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.05.020_bib17","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2023.41.16_suppl.8500","article-title":"Surgical outcomes of patients with resectable non-small-cell lung cancer receiving neoadjuvant immunotherapy with nivolumab plus relatlimab or nivolumab: Findings from the prospective, randomized, multicentric phase II study NEOpredict-Lung","volume":"41","author":"Aigner","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.020_bib18","doi-asserted-by":"crossref","first-page":"101184","DOI":"10.1016\/j.esmoop.2023.101184","article-title":"Anti-TIGIT therapies for solid tumors: a systematic review","volume":"8","author":"Rousseau","year":"2023","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.020_bib19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.020_bib20","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","article-title":"Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses","volume":"40","author":"Joller","year":"2014","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.020_bib21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2026.05.020_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01179","article-title":"Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation","volume":"10","author":"Pende","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.020_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-016-0191-4","article-title":"31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts","volume":"4","author":"Althammer","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.020_bib24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/1078-0432.CCR-21-2635","article-title":"Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck","volume":"28","author":"Hanna","year":"2022","journal-title":"Clin Cancer"},{"issue":"7963","key":"10.1016\/j.hoc.2026.05.020_bib25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"issue":"17_suppl","key":"10.1016\/j.hoc.2026.05.020_bib26","doi-asserted-by":"crossref","first-page":"LBA9503","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9503","article-title":"Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201\/KEYNOTE-942 trial","volume":"41","author":"Khattak","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.020_bib27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hoc.2026.05.020_bib28","doi-asserted-by":"crossref","first-page":"9749363","DOI":"10.1155\/2022\/9749363","article-title":"development of peptide-based vaccines for cancer","volume":"2022","author":"Abd-Aziz","year":"2022","journal-title":"J Oncol"},{"issue":"8_Supplement","key":"10.1016\/j.hoc.2026.05.020_bib29","doi-asserted-by":"crossref","first-page":"CT064","DOI":"10.1158\/1538-7445.AM2023-CT064","article-title":"Abstract CT064: phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy","volume":"83","author":"Patel","year":"2023","journal-title":"Flamingo-01. Cancer Res"},{"issue":"8_Supplement","key":"10.1016\/j.hoc.2026.05.020_bib30","doi-asserted-by":"crossref","first-page":"LB199","DOI":"10.1158\/1538-7445.AM2023-LB199","article-title":"Abstract LB199: A personalized neoantigen vaccine is well tolerated and induces specific T-cell immune response in patients with resected melanoma","volume":"83","author":"Kleine-Kohlbrecher","year":"2023","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.hoc.2026.05.020_bib31","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","article-title":"Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer","volume":"21","author":"Yang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.020_bib32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40425-017-0279-5","article-title":"High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute","volume":"5","author":"Davar","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.020_bib33","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1158\/1078-0432.CCR-21-4239","article-title":"Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells","volume":"28","author":"Goff","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.020_bib34","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J Clin"},{"issue":"7791","key":"10.1016\/j.hoc.2026.05.020_bib35","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"issue":"7791","key":"10.1016\/j.hoc.2026.05.020_bib36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"issue":"7791","key":"10.1016\/j.hoc.2026.05.020_bib37","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.020_bib38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","article-title":"Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer","volume":"55","author":"Meylan","year":"2022","journal-title":"Immunity"},{"issue":"24","key":"10.1016\/j.hoc.2026.05.020_bib39","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1200\/JCO.21.02500","article-title":"Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice","volume":"40","author":"Patel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.020_bib40","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","article-title":"The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy","volume":"33","author":"Gopalakrishnan","year":"2018","journal-title":"Cancer Cell"},{"issue":"6529","key":"10.1016\/j.hoc.2026.05.020_bib41","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"issue":"6529","key":"10.1016\/j.hoc.2026.05.020_bib42","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.020_bib43","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2026.05.020_bib44","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2021.39.15_suppl.8500","article-title":"IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC)","volume":"39","author":"Wakelee","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.020_bib45","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.hoc.2026.05.020_bib46","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"10336","key":"10.1016\/j.hoc.2026.05.020_bib47","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.hoc.2026.05.020_bib48","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.020_bib49","doi-asserted-by":"crossref","first-page":"s163","DOI":"10.25251\/skin.7.supp.163","article-title":"Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB\/C melanoma (CheckMate 76K)","volume":"7","author":"Long","year":"2023","journal-title":"SKIN J Cutan Med"},{"issue":"10358","key":"10.1016\/j.hoc.2026.05.020_bib50","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0140-6736(22)01654-3","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial","volume":"400","author":"Livingstone","year":"2022","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.hoc.2026.05.020_bib51","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III\/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238","volume":"29","author":"Larkin","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.hoc.2026.05.020_bib52","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2026.05.020_bib53","doi-asserted-by":"crossref","first-page":"S912","DOI":"10.1016\/j.annonc.2022.07.930","article-title":"804P Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG\/Keynote-054 double-blinded phase III trial","volume":"33","author":"Eggermont","year":"2022","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2026.05.020_bib54","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.hoc.2026.05.020_bib55","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.020_bib56","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.020_bib57","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.020_bib58","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"Versluis","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.020_bib59","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.020_bib60","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2026.05.020_bib61","doi-asserted-by":"crossref","first-page":"S1389","DOI":"10.1016\/j.annonc.2022.08.016","article-title":"LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study","volume":"33","author":"Chalabi","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:02:01Z","timestamp":1788390121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0889858826000626"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.020","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immuno-Oncology","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}